NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Expands Management Team to Meet Company Momentum, Appoints Brian Dow as Chief Financial Officer
Chief Operating Officer Kurt Becker to Take on Broadened Role Overseeing Global Operations and Research and Development Irvine, California., July 29, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced Read More
Agendia Publishes Unprecedented Full Genome Dataset from MINDACT Trial for the Advancement of Translational Research in Communications Biology
PRESS RELEASE Irvine, California., July 27, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced the publication of MINDACT trial data in the July 27 issue of Communications Biology, a Read More
General Standby Statement
Agendia, Inc. has entered into a Settlement Agreement with the U.S. Department of Justice (DOJ) acting on behalf of the Office of Inspector General of the Department of Health and Human Services (OIG-HHS) to resolve Read More
Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment
PRESS RELEASE Presentations outline how BluePrint® genomic testing enables further categorization of HER2-positive cancer and reclassification of ER+ tumors for patients’ benefit FLEX registry reinforces the clinical and real-world utility of MammaPrint® and BluePrint to Read More
Long-term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint
PRESS RELEASE Median follow up nearing 9 years confirms MINDACT as a positive de-escalation study IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – MAY 29, 2020 – Agendia, Inc., a world leader in precision oncology Read More
Agendia to Showcase New Data at ASCO 2020 That Further Stratifies Breast Cancer Patients for More Precise Therapy Recommendations
PRESS RELEASE Data adds to the growing body of evidence demonstrating the efficacy of Agendia’s MammaPrint® and BluePrint® testing to consistently inform optimal breast cancer treatment planning IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences
PRESS RELEASE Development of MammaPrint®, first FDA-cleared molecular diagnostic test for personalized treatment of breast cancer, considered a landmark achievement in breast cancer testing and treatment Irvine, California and Amsterdam, Netherlands, May 07, 2020 Read More
